Prostatype Genomics AB (publ) (PROGEN.ST)

SEK 10.3

(-8.04%)

Operating Income Summary of Prostatype Genomics AB (publ)

Prostatype Genomics AB (publ)'s latest annual operating income in 2023 was -39.3 Million SEK , down -37.0% from previous year.
Prostatype Genomics AB (publ)'s latest quarterly operating income in 2024 Q2 was -9.7 Million SEK , down 0.0% from previous quarter.
Prostatype Genomics AB (publ) reported an annual operating income of -28.69 Million SEK in 2022, down -84.52% from previous year.
Prostatype Genomics AB (publ) reported an annual operating income of -15.54 Million SEK in 2021, up 6.44% from previous year.
Prostatype Genomics AB (publ) reported a quarterly operating income of -9.7 Million SEK for 2024 Q1, up 9.33% from previous quarter.
Prostatype Genomics AB (publ) reported a quarterly operating income of -7.79 Million SEK for 2023 Q1, up 4.24% from previous quarter.

Annual Operating Income Chart of Prostatype Genomics AB (publ) (2023 - 2015)

Historical Annual Operating Income of Prostatype Genomics AB (publ) (2023 - 2015)

Year	Operating Income	Operating Income Growth
2023	-39.3 Million SEK	-37.0%
2022	-28.69 Million SEK	-84.52%
2021	-15.54 Million SEK	6.44%
2020	-16.61 Million SEK	0.0%
2018	-7.86 Million SEK	14.21%
2017	-9.16 Million SEK	-98.13%
2016	-4.62 Million SEK	59.39%
2015	-11.39 Million SEK	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-9.7 Million SEK	0.0%
2024 Q1	-9.7 Million SEK	9.33%
2023 Q1	-7.79 Million SEK	4.24%
2023 FY	-39.3 Million SEK	-37.0%
2023 Q2	-10.05 Million SEK	-29.04%
2023 Q3	-10.69 Million SEK	-6.38%
2023 Q4	-10.69 Million SEK	0.0%
2022 FY	-28.69 Million SEK	-84.52%
2022 Q4	-8.13 Million SEK	-6.5%
2022 Q3	-7.64 Million SEK	-3.65%
2022 Q2	-7.37 Million SEK	-33.16%
2022 Q1	-5.53 Million SEK	3.43%
2021 Q1	-3.39 Million SEK	13.9%
2021 FY	-15.54 Million SEK	6.44%
2021 Q4	-5.73 Million SEK	-57.71%
2021 Q3	-3.63 Million SEK	-54.68%
2021 Q2	-2.35 Million SEK	30.76%
2020 FY	-16.61 Million SEK	0.0%
2020 Q4	-3.94 Million SEK	-10.2%
2020 Q3	-3.57 Million SEK	-14.12%
2020 Q2	-3.13 Million SEK	-96.42%
2020 Q1	-1.59 Million SEK	12.86%
2019 Q4	-1.83 Million SEK	-79.4%
2019 Q3	-1.02 Million SEK	0.0%
2018 FY	-7.86 Million SEK	14.21%
2017 FY	-9.16 Million SEK	-98.13%
2016 FY	-4.62 Million SEK	59.39%
2015 FY	-11.39 Million SEK	0.0%

Peer Operating Income Comparison of Prostatype Genomics AB (publ)

Name	Operating Income	Operating Income Difference
AroCell AB (publ)	-59.78 Million SEK	34.253%
Devyser Diagnostics AB (publ)	-56.5 Million SEK	30.432%
Immunovia AB (publ)	-296.46 Million SEK	86.742%
SenzaGen AB	-14.74 Million SEK	-166.662%
Spermosens AB	-10.89 Million SEK	-260.804%